Table S16 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Publication
, Other
Paller, CJ; Zahurak, ML; Mandl, A; Metri, NA; Lalji, A; Heath, E; Kelly, WK; Hoimes, C; Barata, P; Taksey, J; Garrison, DA; Patra, K ...
March 26, 2025
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Paller, C. J., Zahurak, M. L., Mandl, A., Metri, N. A., Lalji, A., Heath, E., … Levine, M. (2025). Table S16 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial. https://doi.org/10.1158/2767-9764.28672589
Paller, Channing J., Marianna L. Zahurak, Adel Mandl, Nicole A. Metri, Aliya Lalji, Elisabeth Heath, William K. Kelly, et al. “Table S16 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial,” March 26, 2025. https://doi.org/10.1158/2767-9764.28672589.
Paller CJ, Zahurak ML, Mandl A, Metri NA, Lalji A, Heath E, et al. Table S16 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial. 2025.
Paller, Channing J., et al. Table S16 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial. 26 Mar. 2025. Crossref, doi:10.1158/2767-9764.28672589.
Paller CJ, Zahurak ML, Mandl A, Metri NA, Lalji A, Heath E, Kelly WK, Hoimes C, Barata P, Taksey J, Garrison DA, Patra K, Milne GL, Anders NM, Nauroth JM, Durham JN, Marshall CH, Markowski MC, Eisenberger MA, Antonarakis ES, Carducci MA, Denmeade SR, Levine M. Table S16 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial. 2025.